-transparent.png){kind=logo}
To evaluate mechanisms of diabetes-induced changes in very-low-density lipoprotein (VLDL), VLDL triglyceride (TG) and VLDL apolipoprotein B (apoB) metabolism were studied in 12 obese Pima Indian control subjects and in 15 Pima Indian obese non-insulin-dependent diabetics. Eleven of the diabetics were restudied after reduction of hyperglycemia with oral sulfonylurea therapy. In addition, adipose, muscle, and postheparin lipoprotein lipase and postheparin hepatic lipase activities were measured in all subjects. Obese diabetics as compared with obese controls showed a trend toward increased production of VLDL TG (46 +/- 4 vs. 35 +/- 6 g/day, P = .10) but not of VLDL apoB (1595 +/- 106 vs. 1597 +/- 164 mg/day, NS); production of VLDL TG declined to control levels (33 +/- 4 g/day, P less than .05) during therapy, whereas there was no change in production of VLDL apoB. Diabetics had a clearance defect for VLDL, indicated by significantly lower fractional catabolic rates for both VLDL TG (10.6 +/- .9 vs. 13.1 +/- .9 pools/day, P less than .05) and VLDL apoB (5.6 +/- .4 vs. 7.5 +/- 0.7, P less than .05) as compared with controls; fractional catabolic rates increased after therapy (to 13.3 +/- 1.5, P less than .05, and 6.7 +/- .4, P less than .05, respectively). In the diabetics, this decrease in clearance was accompanied by a lower adipose lipoprotein lipase (.30 +/- .09 vs. .92 +/- .25 mumol X g-1 X h-1, P less than .01), which increased during therapy (to .61 +/- .17, P less than .05). Hepatic lipase also decreased significantly after therapy (27.4 +/- 3.6 to 26.4 +/- 3.2, P less than .01). Composition of VLDL in diabetics was also abnormal, indicated by a higher TG/apoB ratio (14.7 +/- .6 vs. 11.7 +/- .8, P less than .01); this ratio fell during therapy (to 12.5 +/- .8, P less than .05). The data indicate there are multiple abnormalities in structure and metabolism of VLDL in non-insulin-dependent diabetics. Control of hyperglycemia with sulfonylureas has the capability of reversing some of these abnormalities.
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
August 1988,
Klinische Wochenschrift,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
August 1995,
Diabetologia,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
January 1985,
Monographs on atherosclerosis,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
November 2014,
Arthritis research & therapy,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
February 1987,
American heart journal,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
September 1995,
Diabetes,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
December 2006,
American journal of physiology. Endocrinology and metabolism,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
March 1994,
Shock (Augusta, Ga.),
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
January 2013,
PloS one,
M R Taskinen, and
W F Beltz, and
I Harper, and
R M Fields, and
G Schonfeld, and
S M Grundy, and
B V Howard
January 1984,
Agents and actions. Supplements,
